Kymera Therapeutics Inc. has unveiled two new first-in-class oral degrader programs for immune-mediated diseases: KT-621, a STAT6 degrader, and KT-294, a TYK2 degrader.
Human African trypanosomiasis (HAT) is a neglected tropical disease caused by the vector-borne parasites Trypanosoma brucei gambiens or Trypanosoma brucei rhodesiense. Despite the recent approval of fexinidazole, novel antitrypanosomal agents are needed to attain its targeted eradication by 2030.
Metabolic dysfunction-associated fatty liver disease, most commonly known as nonalcoholic fatty liver disease (NAFLD), has a prevalence of about 30% in the general population and about 80% in people with obesity. It is characterized by steatosis and metabolic dysfunction, with inflammation and fibrogenesis.
Kynexis BV recently launched with a series A of €57 million (US$62 million) and a lead asset, Kyn-5356, that targets the kynurenine pathway. The company is preparing for clinical trials that will test the compound for the treatment of cognitive impairment associated with schizophrenia.
Activon Co. Ltd. has described compounds acting as reactive oxygen species (ROS) production inhibitors reported to be useful for the treatment of aging, atopic dermatitis, cardiovascular disorders, cancer, hepatitis, hepatobiliary diseases, neurodegeneration and rheumatoid arthritis.
University of Alberta has divulged 3C-like proteinase (3CLpro; Mpro; nsp5) (SARS-CoV-2; COVID-19 virus) inhibitors reported to be useful for the treatment of viral infections.
Kymera Therapeutics Inc. has identified proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase binding agent coupled to probable global transcription activator SNF2L2 (SMARCA2; BAF190B; SNF2-α) and/or polybromo-1 (PB1) protein targeting moiety via a linker reported to be useful for the treatment of cancer, viral infection, neurodegeneration, liver, metabolic, cardiovascular, genetic and inflammatory disorders, among others.
Researchers at Chia Tai Tianqing Pharmaceutical Group Co. Ltd. and Medshine Discovery Inc. have disclosed bicyclic substituted compounds acting as complement factor B (CFB) inhibitors reported to be useful for the treatment of Parkinson's disease.
Bridgebio Pharma Inc. has obtained FDA clearance for its IND application for BBO-8520, a first-in-class orally bioavailable and potent small-molecule direct inhibitor of KRAS G12C (ON) state. The company expects to begin enrolling patients with KRAS G12C mutant non-small-cell lung cancer (NSCLC) in the first half of this year.
RSS
